Original Articles| Volume 12, ISSUE 1, P17-21, January 2003

Download started.


Effect of edaravone on cerebral vasospasm following experimental subarachnoid hemorrhage


      The effect of the free radical scavenger edaravone on experimental cerebral vasospasm following subarachnoid hemorrhage (SAH) was investigated in a canine double hemorrhage model. Changes in the diameter of the basilar artery were assessed by serial angiography. The diameter ratio at day 7 was calculated as the percent of the basilar artery diameter of a given angiogram with respect to that of its control (day 0). The diameter ratios for the basilar artery following SAH in the control and vehicle-treated groups were 49.7% ± 3.9% (mean ± SEM) and 50.1% ± 1.7%, respectively. Edaravone was administered either by continuous intravenous injection for 7 days or by bolus injection for 7 days. Continuous administration of edaravone (1 mg/kg/hr or 10 mg/kg/hr) significantly attenuated the narrowing of the basilar artery following SAH. The diameter ratios in these groups were 71.3% ± 3.6% (1 mg/kg/hr) and 75.7% ± 1.7% (10 mg/kg/hr). Bolus administration of edaravone (3 mg/kg, every 12 hours) reduced the arterial narrowing following SAH. The diameter ratio on day 7 was 60.1% ± 3.3%, but the difference was not significant. These findings suggest that edaravone is effective in preventing cerebral vasospasm following SAH. Copyright © 2003 by National Stroke Association


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dorsch NWC
        • King MT
        A review of cerebral vasospasm in aneurysmal subarachnoid hemorrhage.
        J Clin Neurosci. 1994; 1: 19-26
        • Gutteridge JMC
        Iron promoters of the Fenton reaction and lipid peroxidation can be released from hemoglobin by peroxides.
        FEBS Lett. 1986; 201: 291-295
        • Kellogg III, EW
        • Fridovich I
        Liposome oxidation and erythrocyte lysis by enzymically generated superoxide and hydrogen peroxide.
        J Biol Chem. 1977; 252: 6721-6728
        • Winterbourn CC
        • McGrath BM
        • Carrell RW
        Reactions involving superoxide and normal and unstable haemoglobin.
        Biochem J. 1976; 155: 493-502
        • Asano T
        • Sasaki T
        • Koide T
        • et al.
        Experimental evaluation of the beneficial effect of an antioxidant on cerebral vasospasm.
        Neurol Res. 1984; 6: 49-53
        • Asano T
        • Takakura K
        • Sano K
        • et al.
        Effects of a hydroxy radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial.
        J Neurosurg. 1996; 84: 792-803
        • Echlin F
        Experimental vasospasm, acute and chronic, due to blood in the subarachnoid space.
        J Neurosurg. 1971; 35: 646-656
        • Fisher CM
        • Kistler JP
        • Davis JM
        Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning.
        Neurosurgery. 1980; 6: 1-9
        • Macdonald RI
        • Weir BKA
        A review of hemoglobin and the pathogenesis of cerebral vasospasm.
        Stroke. 1991; 22: 971-982
        • Mayberg MR
        • Okada T
        • Bark DH
        The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage.
        J Neurosurg. 1990; 72: 634-640
        • Saito I
        • Asano T
        • Sano K
        • et al.
        Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
        Neurosurgery. 1998; 42: 269-277
        • Tanishima T
        Cerebral vasospasm: contractile activity of hemoglobin in isolated canine basilar arteries.
        J Neurosurg. 1980; 53: 787-793
        • Murota S
        • Morita I
        • Suda N
        The control of vascular endothelial injury.
        Ann NY Acad Sci. 1990; 598: 182-187
        • Watanabe T
        • Morita I
        • Nishi H
        • et al.
        Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro.
        Prostaglandins Leukot Essent Fatty Acids. 1988; 33: 81-87
        • Watanabe T
        • Yuki S
        • Egawa M
        • et al.
        Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions.
        J Pharmacol Exp Ther. 1994; 268: 1597-1604
        • Abe K
        • Yuki S
        • Kogure K
        Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger.
        Stroke. 1988; 19: 480-485
        • Kawai H
        • Nakai H
        • Suga M
        • et al.
        Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
        J Pharmacol Exp Ther. 1997; 281: 921-927
        • Mizuno A
        • Umemura K
        • Nakashima M
        Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion.
        Gen Pharmacol. 1998; 30: 575-578
        • Kassell NF
        • Peerless SJ
        • Durward QJ
        • et al.
        Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension.
        Neurosurgery. 1982; 11: 337-343
        • Origitano TC
        • Wascher TM
        • Reichman OH
        • et al.
        Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (triple-H therapy) after subarachnoid hemorrhage.
        Neurosurgery. 1990; 27: 729-739
        • Feigin VL
        • Rinkel GJE
        • Algra A
        • et al.
        Calcium antagonists for aneurysmal subarachnoid hemorrhage.
        Cochrane Database of Systemic Reviews. 2000; ([Cochrane Review]) (Oxford: Update Software)
        • Flamm ES
        • Adams HP
        • Beck DW
        • et al.
        Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage.
        J Neurosurg. 1988; 68: 393-400
        • Pickard JD
        • Murray GD
        • Illingworth R
        • et al.
        Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysmal nimodipine trial.
        Br Med J. 1989; 298: 636-642
        • Shibuya M
        • Suzuki Y
        • Sugita K
        • et al.
        Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial.
        J Neurosurg. 1992; 74: 571-577
        • Findley JM
        • Kassell NF
        • Weir BKA
        • et al.
        A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
        Neurosurgery. 1995; 37: 168-178
        • Kodama N
        • Sasaki T
        • Kawakami M
        • et al.
        Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage.
        Surg Neurol. 2000; 53: 110-118
        • Mizoi K
        • Yoshimoto T
        • Takahashi M
        • et al.
        Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue type plasminogen activator.
        J Neurosurg. 1993; 78: 430-437
        • Nakagomi T
        • Takagi K
        • Narita K
        • et al.
        Cisternal washing therapy for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage.
        Acta Neurochir. 2001; 77: 161-165
        • Ohman J
        • Servo A
        • Heiskanen O
        Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.
        J Neurosurg. 1991; 75: 197-201
        • Sasaki T
        • Ohta T
        • Kikuchi H
        • et al.
        A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
        Neurosurgery. 1994; 35: 597-605
        • Zabranski JM
        • Spetzler RF
        • Lee HKS
        • et al.
        Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with subarachnoid hemorrhage.
        J Neurosurg. 1991; 75: 189-196
        • Finn SS
        • Stephensen SA
        • Miller CA
        • et al.
        Observations on the perioperative management of aneurysmal subarachnoid hemorrhage.
        J Neurosurg. 1986; 65: 48-62
        • Zuccarello M
        • Marsch JT
        • Schmitt G
        • et al.
        Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage.
        J Neurosurg. 1989; 71: 98-104
        • Watanabe T
        • Nishiyama M
        • Hori T
        • et al.
        Ebselen (DR3305) ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model.
        Neurol Res. 1997; 19: 563-565
        • Kassell NF
        • Haley Jr, EC
        • Apperson-Hansen C
        • et al.
        Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.
        J Neurosurg. 1996; 84: 221-228